Progress and challenges towards targeted delivery of cancer therapeutics.

Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. · 2018

Read Progress and challenges towards targeted delivery of cancer therapeutics. by Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5897557.txt.

Description

Rosenblum and co-authors review progress and challenges in targeted cancer drug delivery. Their article appeared in Nature Communications. Interest in targeted delivery has risen steeply for decades. Yet only 15 passive nanocarriers have won clinical approval. No actively targeted carrier has passed clinical trials. The review asks why translation keeps failing. Body barriers clear most carriers before they reach tumours.

Under one percent of passive carriers reach even leaky tumours. The liver's defence cells seize a large share en route. The authors propose criteria for new active targeting designs. Barriers at vessel walls and inside cells get close review. They close with directions for workable tumour targeting.

Catalog record

CREATORRosenblum D, Joshi N, Tao W, Karp JM, Peer D.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE71 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5897557

Browse the full library · About the Tower of Babel